We have reported previously that thromboxane A2 (TXA2) and serotonin (5-HT, 5-hydroxytryptamine) are 
, two different TXA2 and PGH2 receptor antagonists, in eight of 10 and six of seven dogs, respectively. In eight of 10 dogs (group 4), CFVs were abolished with ketanserin (0.66+± 0.12 mg/kg), a 5-HT2 receptor antagonist. In group 2, 3, and 4 dogs, the respective drugs were given so that the minimal dose required to abolished CFVs was administered. In six of six dogs (group 5), a higher dose of ketanserin (i.e., 1.5 mg/kg) was used to abolish CFVs. At death, intracoronary platelet deposition was evaluated by calculating the LAD platelet accumulation ratio (1"'In activity in the LAD/'1`In activity in the circumflex coronary artery) in 43 dogs and, in 22 dogs, by microscopic examination of the LAD. A marked LAD platelet accumulation ratio was found in group 1A dogs at the stenotic site and in segments immediately distal to it. The LAD platelet accumulation ratio was significantly reduced by both the low and the high doses of ketanserin compared with group 1A dogs (p<0.001). However, the two TXA2 receptor antagonists further reduced the LAD platelet accumulation ratio compared with ketanserintreated animals (p<0.01). Microscopic examination confirmed these findings. We conclude that SQ 28668 and SQ 29548, two different TXA2 receptor antagonists, reduce residual intracoronary platelet deposition associated with CFVs in this canine model more effectively than ketanserin, a 5-HT2 receptor antagonist. (Circulation 1988; 78:701-711) In contrast to typical stable angina, unstable angina appears to be caused by a primary decrease in myocardial oxygen delivery rather than by an increase in myocardial oxygen demand. [1] [2] [3] In recent years, increasing importance has been ascribed to platelets and to release of plateletderived vasoactive substances in mediating the development of unstable angina by either mechanical obstruction of a large epicardial vessel or alteration of coronary vasomotor tone, or both. When the endothelial surface of a blood vessel is damaged, platelets adhere to the injured surface and release substances that initiate repair.4 However, in coronary atherosclerosis, the lumen of a large coronary artery may be substantially narrowed as a consequence of platelet aggregation at the site of a severe stenosis and endothelial damage. Furthermore, the local increase in concentration of platelet-derived products at the site of platelet attachment may promote further platelet aggregation and lead to coronary artery vasoconstriction. 5 Folts 
Materials and Methods
Mongrel dogs (weighing [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] kg) of either sex were anesthetized with sodium pentobarbital (30 mg/kg) and ventilated with room air by a Harvard respirator (South Natick, Massachusetts). Arterial and venous catheters were inserted into a common carotid artery and a jugular vein for measurements of systemic arterial pressure and administration of intravenous fluids or drugs, respectively. The heart was exposed through a thoracotomy at the fifth left intercostal space and suspended in a pericardial cradle. A segment of the left anterior descending coronary artery (LAD) was gently dissected free from the surrounding tissue (usually just below the origin of the first major diagonal branch) and a pulsed-wave Doppler flow probe was placed around the LAD proximal to the area to be constricted.7,9'10 "1In-Labeled Platelet Study After instrumentation was completed, blood was withdrawn from each dog to label platelets with [I"'In]8-hydroxyquinoline (oxine) according to a modification of the method of Thakur et al. 13 Briefly, 43 ml blood was withdrawn in a plastic syringe that contained 7 ml acid citrate dextrose. The blood was transferred to 50-ml plastic test tubes and centrifuged at 120g for 20 minutes at room temperature. The platelet-rich plasma was removed from the packed cells and transferred to two 12-ml plastic tubes. The platelet-rich plasma was centrifuged at 1,OOOg for 5 minutes, and the platelet-poor plasma was removed, leaving 0. After incubation, the platelet suspension was centrifuged at 1,OOOg for 5 minutes. the platelet-poor plasma was removed from the top of the platelet button, and the platelets were resuspended gently in 3 ml autologous platelet-poor plasma. Labeling efficiency defined as "'In bound to platelets X100 "'In bound to platelet+ unbound "'In activity was 72% (range, 49-91%). The viability of the platelets after radiolabeling was assessed in vivo by calculating the percentage of administered radioactivity bound to circulating platelets at different time intervals. At 2, 4, 10, 30, and 60 minutes after the radiolabeled platelets were administered to the animals, a 1-ml blood sample was obtained from a peripheral vein. Platelets were isolated as described above, and radioactivity was counted in both the platelet pellet and the platelet-poor plasma. Only a small amount of radioactivity was found in plateletpoor plasma (range, 3-7%). The percent recovery of the radiolabel was calculated by standard methods. '4 In addition, the responsiveness of radiolabeled platelets to various aggregating agents was tested in vitro according to the turbidimetric method of Born'5 and compared with the values obtained before labeling (see below).
Experimental Protocol
After labeling, platelets were reinjected into the dogs and allowed to circulate for 30 minutes. Control hemodynamic variables, including heart rate, arterial blood pressure, and phasic and mean coronary flow velocities, were all recorded continuously on a Hewlett-Packard (Model 7758, Palo Alto, California) eight-channel recorder. A plastic cylindrical constrictor was placed around the LAD below the Doppler flow probe; the constrictor had a residual lumen diameter that abolished or markedly attenuated reactive hyperemia after 10 seconds of total coronary artery occlusion.9,10 Once CFVs were established, they were observed for 30 minutes. During this period, CFV frequency, phasic and mean coronary blood flow velocities, and systemic hemodynamics were continuously recorded. Changes in coronary flow velocity were compared with baseline flow velocity before coronary artery constriction.
Group JA Dogs
Ten of the group IA dogs were killed after 30 additional minutes of CFVs occurring at the nadir of coronary blood flow. The hearts were promptly excised, and the LADs were dissected free from the surrounding tissue. The LAD was divided into proximal (a segment of the LAD proximal to the constrictor that was not manipulated during the experiment), stenotic, immediately distal (1 mm below the constrictor), and distal segments (1-2 cm below the constrictor). Three arterial segments were also obtained from the intact, unmanipulated circumflex coronary artery (Cx). Arterial segments were weighed and placed in a Packard Autogamma gamma spectrometer (Downers Grove, Illinois). The accumulation of`In-labeled platelets was expressed as the increase in "'In radioactivity in the LAD divided by the mean "'In radioactivity in the Cx arterial segments, and it is subsequently referred to as the "LAD platelet accumulation ratio." The raw radioactivity counts in the LAD and Cx segments were divided by the tissue wet weight to yield counts per minute per gram. The increase in "'In radioactivity in the LAD segments was calculated by dividing the activity in each LAD segment (cpm/ g) by the mean activity of the Cx segments, yielding the LAD platelet accumulation ratio.
Group 1B Dogs
Five of the group LB dogs did not develop CFVs after placement of the coronary constrictor. One hour after placement of the constrictor, the dogs in this group were killed, and they underwent the same surgical protocol described for Group LA dogs. Groups mg/kg for ketanserin. Thirty minutes after abolition of CFVs, these animals were killed, and they underwent the same surgical protocol described for group LA dogs.
Group 5 Dogs
Six of the group 5 dogs received a dose of ketanserin (1.5 mg/kg) that was approximately twice the minimal dose necessary to abolish CFVs in group 4 dogs. Thirty minutes after abolition of CFVs, these animals were killed, and they underwent the same surgical protocol described for group LA dogs.
Histological Study
To correlate platelet accumulation assessed by measuring "'In radioactivity with histological find- systemic arterial pressures and heart rates before the CFVs had developed were not significantly different from those recorded after 30 minutes of CFVs. In groups 4 and 5, ketanserin resulted in significant decreases in heart rates and arterial pressures. The frequency of CFVs in group IA dogs was 10.2 + 0.6 cycles/hr. The severity of the cyclic flows, measured by nadir flow that was averaged during several cycles, was 8 + 2% of the mean control velocity before constriction of the coronary artery. The frequency and severity of CFVs were not significantly different in group IA, group 2, group 3, group 4, and group 5 dogs before the administration of saline, SQ 28688, SQ 29548, and ketanserin, respectively (Figure 1 ).
LAD Platelet Accumulation Ratio
To verify that platelet viability was not altered during labeling, an in vivo test was performed assuming that`In-labeled platelets injured during the labeling process were sequestered by the spleen and liver within 30 minutes of administration into the circulatory system.14 In these experiments, an average of 68% of total, administered`In-labeled platelets was present in the circulation after 30 minutes (Figure 2 (Figure 3 ). This increase in "'In activity was even more pronounced in the LAD segments immediately distal to the stenosis where it was 1,458 + 113 (Figure 4 ). Group 1B dogs that did not develop CFVs after placement of the constrictor (n =5) did not show a significant increase in "'In activity at the site of the stenosis or in LAD segments immediately distal to it, 4.7 + 2.4 and 2.3 + 0.7, respectively (Figures 3 and 4) . The administration of two different TXA2 receptor antagonists and ketanserin, a 5-HT2 receptor antagonist at low and high doses, was effective in abolishing CFVs. This was associated with a significant reduction in residual intracoronary platelet accumulation at the site of the stenosis and immediately distal to it compared with accumulation in control dogs (Figures 3 and 4) . In particular, SQ 28688 and SQ 29548 were significantly more effective than both doses of ketanserin in reducing the platelet accumulation ratio in stenotic coronary artery segments: 33+3 and 37 + 8 vs. 148 + 12 and 132 ± 14 (p<0.01, Figure   3 ), and in those segments immediately distal to it: 78 + 15 and 70 ± 6 vs. 318 ± 20 and 286 ± 20 (p<0.01, Figure 4 ). Finally, no significant platelet accumulation was observed in LAD segments greater than 1 cm distal to the constrictor site in all groups: 1.1 ± 0.3 in group 1A, 1.4 + 0.4 in group 1B, 1.4 five low-dose ketanserin-treated dogs (two of which received`'In-labeled platelets), and two high-dose ketanserin-treated dogs that also received`'Inlabeled platelets. Table 2 shows the histological score of intracoronary platelet accumulation for these animals. The highest histological scores (associated with intense "'In-activity) were observed in control dogs killed at the nadir of coronary blood flow (group lA) ( Figure 5 ), whereas the lowest scores (associated with only mild or moderate "'Inactivity) were observed in dogs treated with SQ 28668 and SQ 29548 ( Figure 6 ). Dogs whose CFVs were abolished by both low and the high doses of ketanserin showed intermediate histological scores (Figure 7 ).
Platelet Aggregation Studies
ADP at the concentration of 10 gtm induced maximal, irreversible aggregation. Canine platelets failed to aggregate in response to either U46619 or serotonin alone. However, a subaggregatory concentration of epinephrine (10 ,M) sensitized canine platelets to U46619 and serotonin. Serotonin, at a 10-MiM concentration, caused maximal aggregation responses in epinephrine-primed platelets isolated from group 5 dogs (n = 6) before the administration of ketanserin (Figure 8 ). Serotonin aggregation (10 ,uM) in epinephrine-primed platelets isolated from the same animals after administration of 1.5 mg/kg ketanserin was completely inhibited (Figure 8 ). Ketanserin did not change maximal platelet aggregation induced by ADP or U46619. Therefore, ketanserin, at the dose of 1.5 mg/kg, completely and selectively blocked 5-HT2 platelet receptors.
Discussion In this experimental model, endothelial damage associated with a coronary stenosis severe enough to abolish or markedly attenuate the hyperemic By labeling autologous platelets with "'in, we have been able to quantify the residual intracoronary platelet deposition in dogs in which CFVs were abolished by means of different interventions. Dogs that received no treatment and that were killed during the nadir of their coronary blood flow were compared with dogs in which TXA2 and PGH2 receptor antagonism was achieved by means of two different drugs, namely, SQ 28668 and SQ 29548, and with dogs receiving a low and a high dose of the 5-HT2 receptor antagonist ketanserin. As expected, marked platelet accumulation occurred at the site of the stenosis and endothelial injury in coronary arteries obtained from untreated control dogs that were killed during the nadir of their coronary blood flow. Interestingly, in the same group of dogs, LAD segments immediately distal to the constricted segments showed a higher platelet accumulation ratio than was observed in stenotic segments.
Platelets possess properties that permit them to adhere to and aggregate at sites of blood vessel injury, which aids in their role in primary hemostasis. These properties of adhesion and aggregation also contribute to the formation of occlusive platelet thrombi in arteries where local shear conditions favor the deposition ofplatelets on the vessel wall. 19, 20 It appears that platelet deposition on the deendothelialized vessel wall is directly related to the shear rate. '19,2122 On the other hand, the sudden expansion of the vessel at the site of the poststenotic segment is known to cause an increase in the shear rate and formation of turbulent flow23 that, in turn, may help to explain the higher platelet accumulation ratio we found in poststenotic segments of the LAD as compared with the stenotic segments.
Platelets are activated in response to a variety of substances in vivo and in vitro. It is believed, however, that platelet activation occurs through three different and independent pathways, including the ADP pathway,24 the arachidonate pathway,25 and the recently proposed platelet-activating factor pathway.26 Platelet agonists can be subdivided into groups depending on their potency. 27 The potency of an agonist is determined by how many different platelet responses it induces and by the extent of its platelet activation. Each of the platelet agonists interacts with specific receptors on the platelet surface, which, in turn, leads to an increase in the cytoplasmic concentration of Ca2 . 27 U46619 (a TXA2 mimetic)-induced canine platelet aggregation than serotonin-induced aggregation. 30 The specificity of ketanserin in blocking both vascular and platelet 5-HT2 receptors has been well documented. 18 28668 and SQ 29548 were more potent than ketanserin in reducing platelet aggregation at sites of endothelial injury when each receptor antagonist was given in the minimal concentrations required to abolish CFVs. These differences cannot be attributed to the fact that ketanserin only partially blocked the 5-HT2 receptor on platelets. In fact, in group 5 dogs that received a dose of ketanserin about twice as large as the minimal dose required to abolish CFVs, the residual intracoronary platelet accumulation was still higher than that observed in dogs treated with the two TXA2 antagonists. In group 5 dogs, serotonin-induced aggregation of epinephrineprimed platelets was completely blocked after in vivo administration of ketanserin, thus supporting the hypothesis that a complete blockade of the 5-HT2 receptors was achieved. The significantly lower residual intracoronary platelet deposition obtained with either TXA2 and PGH2 receptor antagonists resulted in a restoration of a mean coronary blood-flow velocity that was not different from the nonconstricted control values. In contrast, abolition of CFVs with both doses of ketanserin resulted in a mean coronary blood-flow velocity that was significantly lower than the nonconstricted control values. Alternatively, the lower mean coronary blood-flow velocity observed in ketanserin-treated animals may be the result of a reduced pressure gradient across the coronary stenosis due to a reduction in systemic blood pressure after administration of the drug. It is therefore possible that the higher residual intracoronary platelet accumulation we observed in the ketanserin-treated animals could be explained, at least in part, by hemodynamic factors. In fact, a reduced pressure gradient across the stenosis may result in a reduced number of platelets removed after abolition of CFVs. However, it is also possible that in this model, blockade of the 5-HT2 receptors by ketanserin represents an intervention capable of attenuating further platelet deposition but not powerful enough to induce disaggregation of most of the platelets already forming an intravascular plug. In contrast, TXA2 and PGH2 receptor antagonism seems to be very elfective both in abolishing CFVs and in reducing LAD platelet accumulation.
In conclusion, the role of intracoronary platelet activation as either a primary or secondary event in the pathogenesis of acute ischemic heart disease syndromes is becoming increasingly accepted. 
